Spark Therapeutics price target raised to $98 from $78 at BMO Capital. BMO Capital analyst Matthew Luchini raised his price target on Spark Therapeutics to $98 after his investor meetings with the management. The analyst says the discussions focused on the launch of Luxturna, the upcoming HemA data, and the company’s gene therapy reimbursement, adding that while the metrics of the first are “encouraging”, the reimbursement negotiations hinge on larger indications. Luchini keeps his Outperform rating, citing his price target revision to higher conviction in HemA as well as his updated pricing and spending assumptions for Spark Therapeutics’ products
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.